1. Home
  2. IRWD vs BCAL Comparison

IRWD vs BCAL Comparison

Compare IRWD & BCAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.57

Market Cap

663.6M

Sector

Health Care

ML Signal

HOLD

Logo Southern California Bancorp

BCAL

Southern California Bancorp

HOLD

Current Price

$19.66

Market Cap

637.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRWD
BCAL
Founded
1998
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
663.6M
637.5M
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
IRWD
BCAL
Price
$3.57
$19.66
Analyst Decision
Buy
Buy
Analyst Count
3
3
Target Price
$7.67
$20.67
AVG Volume (30 Days)
2.0M
141.4K
Earning Date
05-11-2026
04-28-2026
Dividend Yield
N/A
2.15%
EPS Growth
1400.00
777.27
EPS
0.24
0.42
Revenue
$298,276,000.00
N/A
Revenue This Year
$57.95
N/A
Revenue Next Year
$4.39
$6.67
P/E Ratio
$14.73
$46.31
Revenue Growth
8.88
N/A
52 Week Low
$0.66
$14.30
52 Week High
$5.78
$20.47

Technical Indicators

Market Signals
Indicator
IRWD
BCAL
Relative Strength Index (RSI) 48.48 58.53
Support Level $3.08 $17.97
Resistance Level $3.95 $19.91
Average True Range (ATR) 0.19 0.49
MACD 0.04 0.01
Stochastic Oscillator 67.44 82.69

Price Performance

Historical Comparison
IRWD
BCAL

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

About BCAL Southern California Bancorp

California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.

Share on Social Networks: